ZNF582 Inhibitors
Chemical inhibitors of ZNF582 can influence the activity of this protein through various biochemical pathways by blocking the phosphorylation processes essential for its function. Staurosporine, for example, is a broad-spectrum protein kinase inhibitor that can inhibit the phosphorylation of ZNF582, thus preventing any activation or interaction that depends on this post-translational modification. Similarly, Bisindolylmaleimide I targets protein kinase C (PKC), which is crucial for the phosphorylation of many proteins. By inhibiting PKC, Bisindolylmaleimide I can reduce the phosphorylation and consequently the activity of ZNF582 if PKC mediates its activation. LY294002 and Wortmannin are both inhibitors of PI3K, which is upstream of AKT, a kinase that can phosphorylate various substrates including transcription factors. The inhibition of PI3K by these chemicals results in reduced AKT activity, leading to a decrease in the phosphorylation and subsequent activity of ZNF582.
Inhibitors that target the MAPK pathway, such as PD98059 and U0126, can also reduce ZNF582 activity. PD98059 inhibits MEK, which is necessary for the activation of ERK1/2, and U0126 selectively inhibits MEK1 and MEK2, preventing the activation of downstream ERKs. These inhibitory actions can lead to a decrease in ZNF582 function if its activity is regulated by the MAPK/ERK pathway. Additionally, SP600125 and SB203580 inhibit the JNK and p38 MAP kinase pathways, respectively. The inhibition of these kinases can lead to reduced ZNF582 activity if JNK or p38 MAPK regulate this protein. Rapamycin, an mTOR inhibitor, can also reduce ZNF582 activity by inhibiting downstream signaling pathways that regulate transcriptional activity or protein synthesis. Furthermore, Y-27632's ability to inhibit ROCK affects cytoskeleton organization, which can influence the localization and thus the function of ZNF582 within the cell. Lastly, PP2, which inhibits Src family tyrosine kinases, and Alsterpaullone, a CDK inhibitor, can decrease the activity of ZNF582 by preventing its phosphorylation by these kinases if it is one of their substrates.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. It can inhibit the phosphorylation of ZNF582, thereby preventing any phosphorylation-dependent functional activation or interaction of ZNF582 with other cellular components. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I specifically inhibits protein kinase C (PKC). Inhibition of PKC can lead to reduced phosphorylation of transcription factors including ZNF582, which may rely on PKC for activation or localization to specific genomic regions. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of PI3K. By inhibiting PI3K, it can lead to a reduction in AKT phosphorylation and activity. Since AKT can regulate a variety of transcription factors, its inhibition can result in decreased functional activity of ZNF582 through reduced signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which subsequently inhibits ERK1/2 activation. ZNF582, as a transcription factor, may depend on the MAPK/ERK pathway for its activation or nuclear localization, and inhibition of this pathway can inhibit the function of ZNF582. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which can affect transcription factors through phosphorylation. By inhibiting JNK, SP600125 can inhibit the phosphorylation and therefore the activity of ZNF582 if it is a substrate for JNK. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. The p38 MAPK pathway can regulate transcription factors; thus, inhibition by SB203580 could lead to a functional inhibition of ZNF582 if it is regulated by this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. By inhibiting mTOR, Rapamycin can inhibit downstream signaling pathways that might regulate transcriptional activity or protein synthesis, potentially leading to functional inhibition of ZNF582. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor, similar to LY294002, and can inhibit the AKT signaling pathway. Through this pathway's inhibition, the activity of transcription factors such as ZNF582 can be reduced due to decreased downstream signaling. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 inhibits ROCK, which can influence cytoskeleton organization and potentially nuclear-cytoplasmic transport. This may inhibit the function of ZNF582 by preventing its proper localization within the cell. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of both MEK1 and MEK2. MEK inhibition can prevent the activation of downstream ERKs, potentially leading to a decrease in the functional activity of transcription factors such as ZNF582. | ||||||